CN ChemNet > Gold Suppliers > Fujian Wanke Pharmaceutical Co.,Ltd.
About Us
    Fujian Vanke Pharmaceutical Co., Ltd. attracted investment to invest in Jiangle county ,Sanming City for pharmaceutical API and intermediates in 2011, covering an area of 100 mu.Vanke Pharmaceutical is committed to the research and development and production of senile diseases (such as hypertension, diabetes), antiviral, anticancer drugs and other pharmaceutical API and pharmaceutical intermediates, forming a set of perfect research and development, production and sales management system.The first phase of Vanke Pharmaceutical has built a construction area of 13,000 ㎡, including workshop a, workshop b, warehouse a, warehouse b, mechanical and electrical workshop, refrigeration workshop, scientific research building, power distribution room, sewage treatment facilities, etc. In 2015, the company was listed in the key project enterprise in Fujian Province, identified as the leading enterprise of science and technology giant in Fujian Province in 2016, in 2016, won the national high-tech enterprise, passed iso9001 quality management system certification, iso14001 environmental management system certification, iso45001,1 invention patent and 8 utility model patents. In 2019, Vanke Pharmaceutical carried out project restructuring, invested 45 million yuan in restructuring and technical reform funds, and added a new vitamin d3 production line.After the reorganization of the company, it will build a new high-tech enterprise with a new attitude.At present, the company's main products are Aminoacetaldehyde dimethyl acetal, Methylamino acetaldehyde dimethyl acetal vitamin d3, The annual output of Aminoacetaldehyde dimethyl acetal is 150 tons, The output value is about 40million yuan, A net profit of 15 million yuan, Currently accounts for 50% of the domestic market, For 30% of the international market, Have a complete and comprehensive product production and opening qualification, The product has a wide range of applications, It can be used as an intermediate in the anti-AIDS new drug dolutegravir,, ivabradine hydrochloride, praziquantel and other drugs, On April 6,2022, a phase III clinical trial of The anti-coronavirus drug proclutamine, This means that the market demand for Aminoacetaldehyde dimethyl acetal will continue to expand, For this end, the company plans to expand its production capacity to 200 tons / year by June2022.The new product vitamin d3 was completed in September 2021, and the process trial production and relevant licensing procedures are currently being completed. At the end of 2020, the second phase of biotin and vitamin series production project began in preparation.Civil construction began in September 2021.Civil construction is expected to be completed in June 2022.The total investment of the project is about 300 million yuan, including a fixed investment of about 120 million yuan for civil engineering, about 150 million yuan for equipment investment, and about 30 million yuan for other ancillary facilities and automation control systems.After the completion of the project, the annual output value is expected to be 600 million yuan, with a profit of 150 million yuan, a tax revenue of about 50 million yuan, and 200 employed employees. Adhering to the cultural concept of "sharing, sharing", take customer satisfaction, provide high quality and efficient products and services; warmly welcome relevant companies, organizations and customers for consultation and cooperation.
Contact us
Contact:
  Angela lin
Phone:
+86-598-5028111
Mobile phone:
+86 15859250346
Fax:
+86-598-5026002
E-mail:
angela@wankepharm.com
Website:
http://www.wankepharm.com www.chongyichem.com
Zip Code:
353300
Address:
No.26, Pengcheng Avenue, Jishan Industrial Park, Jiangle County, Sanming City, Fujian Province 353300, P.R. China
World Wide ChemNet: - International - China - U.S.E - urope - India - Japan - China(Taiwan) - Korea - Trading Circle
About Us - Top Products- Partner with Us - Contact Us - Help - Sitemap
ChemNet is a registered trademark of Zhejiang NetSun Co., Ltd.